| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $0 | 3 | 100 |
| Mitrany Rayten Michal Ety | director | 0 | $0 | 2 | $0 | $0 |
| Moiseyev Gilad | Chief Technology Officer | 0 | $0 | 1 | $0 | $0 |
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, …
Over the last 12 months, insiders at BrainsWay Ltd. have bought $0 and sold $0 worth of BrainsWay Ltd. stock.
On average, over the past 5 years, insiders at BrainsWay Ltd. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-06-15 | Sale | Moiseyev Gilad | Chief Technology Officer | 5,000 – | $0 | $0 | +0.07% | |
| 2026-05-26 | Sale | Mitrany Rayten Michal Ety | director | 7,980 – | $0 | $0 | -9.41% | |
| 2026-05-25 | Sale | Mitrany Rayten Michal Ety | director | 10,000 – | $0 | $0 | -9.38% |
| Increased Positions | 24 | +48.98% | 957,433 | +17.58% |
| Decreased Positions | 21 | -42.86% | 457,715 | -8.4% |
| New Positions | 7 | New | 201,734 | New |
| Sold Out Positions | 8 | Sold Out | 226,778 | Sold Out |
| Total Postitions | 52 | +6.12% | 6M | +9.17% |